A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
The main purpose of this study is to compare donanemab to aducanumab on amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have had slow or rapid change in memory for the last 6 months
Participant must have a reliable study partner with whom they have regular contact and who can provide written informed consent to participate and attend study appointments
Participants Must Not:
Participants must not have a significant disease of the brain such as Parkinson's disease, multiple concussions, that affects completion of the study
Participants must not have history of heart attack or stroke, epilepsy or seizures
Participants must not have serious or unstable illness that could interfere with the analysis of the study or have a life expectancy <24 months
Participants must not have serious risk for suicide
Participants must not have a history of severe drug allergies
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo